
AFFIRMO cluster trial finds mHealth and geriatric assessment did not reduce hospitalizations in older atrial fibrillation patients already receiving guideline care
AI-summarized from the linked source. Educational brief, not medical advice.
Brief summary
The 6-country AFFIRMO cluster-randomized trial of 1,260 older multimorbid atrial fibrillation patients found that adding a mobile health integrated care and comprehensive geriatric assessment system did not decrease unplanned hospitalizations (17.1% vs 18.2%) in a population already exhibiting 97.3% baseline guideline adherence.
What NurseJet pulled from the source
Older patients with atrial fibrillation frequently present with complex multimorbidity and polypharmacy, driving hospitalizations and adverse cardiovascular events. The AFFIRMO trial, an open-label cluster-randomized study conducted across clinical centers in six European countries, evaluated whether an integrated care system (iABC) combining mobile health tracking with comprehensive geriatric assessment reduced clinical outcomes compared to guideline-based usual care. The trial enrolled 1,260 patients (mean age 74 years; 44.4% female; median CHA2DS2-VASc score 4; 41.0% with >2 comorbidities) across allocated clusters (634 intervention, 626 usual care). Baseline guideline adherence was exceptionally high, with 97.3% (1,226/1,260) already receiving oral anticoagulation. Over follow-up, the primary endpoint of all-cause unplanned hospitalization occurred in 108 (17.1%) intervention patients and 114 (18.2%) usual care patients (adjusted OR 0.95; 95% CI 0.61 to 1.49; P = 0.84). Digital app engagement was low, with 68.5% of intervention participants utilizing the mobile platform for only one-third of the study duration.
Why this matters for nurses
Cardiovascular and telemetry nurses frequently coordinate discharge teaching and digital health tools for older adults with arrhythmias. This robust trial demonstrates that digital health platforms yield no measurable clinical benefit when foundational guideline care is already high, and underscores that tech-dependent solutions must address real-world usability challenges among older adults.
Bedside takeaway
In the 1,260-patient AFFIRMO trial of older multimorbid AF patients with 97% baseline anticoagulation, adding mHealth-guided care did not lower unplanned hospitalizations (17.1% vs 18.2%), constrained by low app adoption.
Key takeaways
- Multicenter cluster-randomized trial enrolled 1,260 older adults with atrial fibrillation and multiple chronic conditions across six European nations.
- Baseline anticoagulation adherence was exceptionally high at 97.3%, and comprehensive geriatric assessment revealed high baseline functional independence.
- Unplanned hospitalizations did not differ significantly between the mHealth integrated care group and usual guideline care (17.1% vs 18.2%, P = 0.84).
- Digital intervention engagement was suboptimal, with over two-thirds of older participants actively using the mobile app for only one-third of follow-up.
Practice implications
- Emphasize reliable adherence to evidence-based oral anticoagulation and rhythm/rate medications during cardiac nursing discharge education, rather than relying on unproven digital health apps, and directly assess older patients for device usability and digital literacy before recommending mobile tracking.
Limitations & cautions
- Open-label cluster design; baseline guideline adherence was extraordinarily high (97.3%), creating an event floor; suboptimal patient adoption of the smartphone application limited potential intervention impact.
- AI-summarized from the linked source. Review the original article before applying to practice.
Citations
Exact source links
Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.
The Lancet regional health. Europe (PubMed)
The Lancet regional health. Europe (PubMed). Integrated care management and comprehensive geriatric assessment using a mHealth-based approach in older multimorbid patients with atrial fibrillation: the AFFIRMO cluster-randomised trial.
https://pubmed.ncbi.nlm.nih.gov/42819749/
Professional education only


